SUB-SAHARAN AFRICA

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key Countries

Botswana
Kenya
Namibia
South Africa
Tanzania

Contribution to Group revenue

Revenue contribution - by therapeutic category

The South African private pharmaceutical sector was valued at R42,9 billion for the year ended 30 June 2018.
Aspen is ranked as the number one pharmaceutical company in the South African private sector with a 12,9% share by value.
About one in every five scripts dispensed by South African pharmacists is for an Aspen product, as recorded by ImpactRx.
In South Africa, six out of the top 25 brands in the private sector for the year ended 30 June 2018 were Aspen products.
Aspen has a strong presence in East Africa through Beta Kenya and Shelys Tanzania.

Source: June 2018 IMS

STATISTICS

Number of products launched:

10

(2017: 11)

IMS* value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD119 million

3 – 5 years

USD250 million

Number of product recalls:

8

(2017: 1)

Average staff turnover:

9,4%

(2017: 13,0%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

* South Africa only, rest of SSA not covered by IMS.# The number of product launches has been restated as a result of the refinement of the product launch definition.

Revenue – R’billion	2018	2017 (CER)	% change
Total	10 008	9 571	5
Commercial Pharmaceuticals	8 127	7 402	10
Regional Brands	7 876	7 124	11
Anaesthetics	143	145	(1)
Thrombosis	9	7	29
High Potency & Cytotoxics	99	126	(21)
Nutritionals	1 017	977	4
Manufacturing	864	1 192	(28)
– API	332	217	53
– FDF	532	975	(45)

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture